Publications by authors named "C Chithra Chandrasekharan"
Surgical Management of Neuroendocrine Tumor Liver Metastases.
Hematol Oncol Clin North Am
February 2025
Patients with neuroendocrine tumor liver metastases (NETLMs) may develop carcinoid syndrome, carcinoid heart disease, or other symptoms from overproduction of hormones. Hepatic resection and cytoreduction is the most direct treatment of NETLMs in eligible patients, and cytoreduction improves symptoms, may reduce the sequelae of carcinoid syndrome, and extends survival. Parenchymal-sparing procedures, such as ablation and enucleation, should be considered during cytoreduction to maximize treatment of multifocal tumors while preserving healthy liver tissue.
View Article and Find Full Text PDFBackground: Peptide receptor radionuclide therapy (PRRT) is an effective treatment for advanced gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). We investigated a 2-decade experience with PRRT to determine whether PRRT confers a survival advantage to patients who progress after surgery versus other therapies.
Methods: We identified patients from our clinic who had resection/cytoreduction of GEP-NETs, then disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.
Article Synopsis
- - Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) were studied to see if high-dose intravenous vitamin C (P-AscH) could improve survival when added to standard chemotherapy (gemcitabine and nab-paclitaxel).
- - The study involved 36 participants, with 34 receiving their assigned treatment, and found that adding P-AscH significantly increased overall survival to 16 months compared to 8.3 months for chemotherapy alone, as well as improved progression-free survival.
- - Importantly, the addition of P-AscH did not harm patients' quality of life or increase side effects, suggesting it is a safe and beneficial adjunct treatment.